{"entity":{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","aka":[],"tldr":"Nobody publishes how much cancer isotope is made, where, or when supply will fall short. A public observatory would let hospitals and investors plan.","summary":"Supply and demand for lutetium-177, actinium-225, iodine-131 and their precursors are opaque; producers guard volumes, and shortages surface only when clinics cancel doses. The proposal is an observatory, hosted by the IAEA or OECD NEA with WHO, that collects confidential production and capacity data from producers under aggregation rules, publishes quarterly supply-demand balances and five-year forecasts, and issues shortage alerts to clinics and regulators. It would also track trial-stage demand so producers can invest ahead of approvals.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy","targeted-alpha-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-data-silos"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Publication of forecasts is followed by earlier capacity investment decisions (measured by announced projects relative to forecast shortfalls) and a fall in unanticipated clinic-level shortages within three years.","rationale":"Transparent supply data (as in energy and food markets) reduce boom-bust investment and allow health systems to plan; the molybdenum-99 experience showed that opaque supply led to repeated crises.","test":"Establish the observatory for lutetium-177 first, publish two years of quarterly balances, and evaluate accuracy of forecasts and changes in shortage reports.","maturity":"speculative","actor":"data","cost":"small","horizonYears":2},"route":"/ideas/idea-reg-isotope-supply-observatory/","neighbours":{"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"bottleneck":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}